Geron Corporation (BIT:1GERN)

Italy flag Italy · Delayed Price · Currency is EUR
1.066
+0.025 (2.40%)
At close: Dec 3, 2025
-14.92%
Market Cap 718.84M
Revenue (ttm) 156.31M
Net Income (ttm) -68.18M
Shares Out n/a
EPS (ttm) -0.10
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,000
Average Volume 1,228
Open 1.096
Previous Close 1.041
Day's Range 1.096 - 1.096
52-Week Range 0.938 - 1.390
Beta n/a
RSI 58.63
Earnings Date Feb 26, 2026

About Geron

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1990
Employees 229
Stock Exchange Borsa Italiana
Ticker Symbol 1GERN
Full Company Profile

Financial Performance

In 2024, Geron's revenue was $76.99 million, an increase of 32386.92% compared to the previous year's $237,000. Losses were -$174.57 million, -5.19% less than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.